CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion

Journal of Immunology

Volumn 177, Issue 5, 2006, Pages 2976-2984

  Xia, Dajing ^a   Hao, Siguo ^a   Xiang, Jim ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Saskatoon Cancer Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; CANCER MODEL; CD8+ T LYMPHOCYTE; CELL KINETICS; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR; TUMOR IMMUNITY;

EID: 33747803052     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.5.2976     Document Type: Article

References (47)

1. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
2. Buller, R. M., K. L. Holmes, A. Hugin, T. N. Frederickson, and H. C. Morse, 3rd. 1987. Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature 328: 77-79.
3. + suppressor T cells. J. Immunol. 156: 916-921.
4. Hou, S., X. Y. Mo, L. Hyland, and P. C. Doherty. 1995. Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins. J. Virol. 69: 1429-1434.
5. + T cell help. J. Exp. Med. 186: 65-70.
6. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
7. Lanzavecchia, A., and F. Sallusto. 2002. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol. 2: 982-987.
8. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258.
9. Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. Dustin. 1999. The immunological synapse: a molecular machine controlling T cell activation. Science 285: 221-227.
10. Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia. 1999. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 283: 680-682.
11. Huang, J. F., Y. Yang, H. Sepulveda, W. Shi, I. Hwang, P. A. Peterson, M. R. Jackson, J. Sprent, and Z. Cai. 1999. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science 286: 952-954.
12. Hwang, I., J. F. Huang, H. Kishimoto, A. Brunmark, P. A. Peterson, M. R. Jackson, C. D. Surh, Z. Cai, and J. Sprent. 2000. T cells can use either T cell receptor or CD28 receptors to absorb and internalize cell surface molecules derived from antigen-presenting cells. J. Exp. Med. 191: 1137-1148.
13. + T helper-antigen-presenting cells. J. Immunol. 174: 7497-7505.
14. Foulds, K. E., L. A. Zenewicz, D. J. Shedlock, J. Jiang, A. E. Troy, and H. Shen. 2002. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. 168: 1528-1532.
15. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
16. Chen, Z., S. Dehm, K. Bonham, H. Kamencic, B. Juurlink, X. Zhang, J. R. Gordon, and J. Xiang. 2001. DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell. Immunol. 214: 60-71.
17. Zhang, W., Z. Chen, F. Li, H. Kamencic, B. Juurlink, J. R. Gordon, and J. Xiang. 2003. Tumour necrosis factor-α (TNF-α) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-α. Immunology 108: 177-188.
18. Nishimura, T., K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, and A. Ohta. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190: 617-627.
19. + T helper-antigen-presenting cells. J. Immunol. 174: 7497-7505.
20. Sansom, D. M., and N. D. Hall. 1993. B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro. Eur. J. Immunol. 23: 295-298.
21. Tatari-Calderone, Z., R. T. Semnani, T. B. Nutman, J. Schlom, and H. Sabzevari. 2002. Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction. J. Immunol. 169: 6162-6169.
22. + T cells involving acquired MHC class II:peptide complexes: another mechanism to limit clonal expansion? Blood 101: 2704-2710.
23. Undale, A. H., P. J. van den Elsen, and E. Celis. 2004. Antigen-independent acquisition of MHC class II molecules by human T lymphocytes. Int. Immunol. 16: 1523-1533.
24. Dutton, R. W., L. M. Bradley, and S. L. Swain. 1998. T cell memory. Annu. Rev. Immunol. 16: 201-223.
25. Kennedy, R., A. H. Undale, W. C. Kieper, M. S. Block, L. R. Pease, and E. Celis. 2005. Direct cross-priming by Th lymphocytes generates memory cytotoxic T cell responses. J. Immunol. 174: 3967-3977.
26. Kaech, S. M., J. T. Tan, E. J. Wherry, B. T. Konieczny, C. D. Surh, and R. Ahmed. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4: 1191-1198.
27. + cells. J. Exp. Med. 195: 1523-1532.
28. Rock, K. L., S. Gamble, and L. Rothstein. 1990. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249: 918-921.
29. Zinkernagel, R. M. 2002. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 32: 2385-2392.
30. + T cells. I. Involvement of the CD80-CD28 adhesion molecules. J. Immunol. 155: 118-127.
31. Taams, L. S., W. van Eden, and M. H. Wauben. 1999. Antigen presentation by T cells versus professional antigen-presenting cells (APC): differential consequences for T cell activation and subsequent T cell-APC interactions. Eur. J. Immunol. 29: 1543-1550.
32. Mannie, M. D., S. K. Rendall, P. Y. Arnold, J. P. Nardella, and G. A. White. 1996. Anergy-associated T cell antigen presentation: a mechanism of infectious tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 157: 1062-1070.
33. Nisini, R., A. Fattorossi, C. Ferlini, and R. D'Amelio. 1996. One cause for the apparent inability of human T cell clones to function as professional superantigen-presenting cells is autoactivation. Eur. J. Immunol. 26: 797-803.
34. Brandes, M., K. Willimann, and B. Moser. 2005. Professional antigen-presentation function by human γδ T Cells. Science 309: 264-268.
35. + T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. 4: 579-585.
36. + T cell activation by dendritic cells in lymph nodes. J. Exp. Med. 200: 847-856.
37. Hou, W. S., and L. Van Parijs. 2004. A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat. Immunol. 5: 583-589.
38. L is critical for dendritic cell survival in vivo. J. Immunol. 173: 4425-4432.
39. Nopora, A., and T. Brocker. 2002. Bcl-2 controls dendritic cell longevity in vivo. J. Immunol. 169: 3006-3014.
40. Ashcroft, A. J., S. M. Cruickshank, P. I. Croucher, M. J. Perry, S. Rollinson, J. M. Lippitt, J. A. Child, C. Dunstan, P. J. Felsburg, G. J. Morgan, and S. R. Carding. 2003. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19: 849-861.
41. + T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J. Immunol. 164: 3095-3101.
42. + T cells in vivo. Proc. Natl. Acad. Sci. USA 103: 147-152.
43. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101: 4260-4266.
44. + effector memory T cells. J. Immunol. 175: 1433-1439.
45. high) subset. J. Immunol. 174: 5341-5350.
46. Dobrzanski, M. J., J. B. Reome, J. A. Hollenbaugh, and R. W. Dutton. 2004. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J. Immunol. 172: 1380-1390.
47. Wang, L. X., J. Kjaergaard, P. A. Cohen, S. Shu, and G. E. Plautz. 2004. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J. Immunol. 172: 3462-3468.